ENDLOS-TURBO PUT - MODERNA | Market Closed - Boerse Frankfurt Warrants 15:34:52 2024-07-15 EDT | ||
| 4.88 EUR | -0.20% |
|
| Current month | -5.51% | ||
| 1 month | +51.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-15 | 4.97 | +1.64% |
| 24-07-12 | 4.89 | +2.73% |
| 24-07-11 | 4.76 | -9.85% |
| 24-07-10 | 5.28 | -2.76% |
| 24-07-09 | 5.43 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update July 15, 2024 at 03:34 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | DZ BANK |
| WKN | DQ284P |
| ISIN | DE000DQ284P6 |
| Date issued | 2024-05-06 |
| Strike | 174.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.642 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.58 € |
|---|---|
| Lowest since issue | 0.66 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.10%
- Stock Market
- Certificates
- Certificat
